Ultragenyx Pharmaceutical Inc
Research Ultragenyx Pharmaceutical Inc (RARE) on Bullrun: market cap USD 2.60B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRARE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.60B
- Financial periodQ2 2026
- RevenueUSD 214.00M
- Net income-USD 92.00M
- Free cash flow-USD 98.00M
- Gross margin84.1%
Valuation Snapshot
latest market cap is USD 2.60B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 673.00M | -USD 575.00M | -USD 472.00M | 83.8% | -5.83 | USD 421.00M | USD 36.00M | -USD 80.00M |
| FY2024 | USD 560.00M | -USD 569.00M | -USD 421.00M | 86.3% | -6.29 | USD 174.00M | USD 40.00M | USD 255.00M |
| FY2023 | USD 434.00M | -USD 607.00M | -USD 519.00M | n/a | -8.25 | USD 214.00M | USD 43.17M | USD 275.00M |
| FY2022 | USD 363.33M | -USD 707.42M | -USD 496.59M | n/a | -10.12 | USD 132.94M | USD 37.53M | USD 352.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.60B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.22B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.89B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.93B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.25B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.83B | n/a | n/a | n/a |
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ultragenyx Pharmaceutical Inc's market cap?
Ultragenyx Pharmaceutical Inc's market capitalization is USD 2.60B.
What does Ultragenyx Pharmaceutical Inc do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.